Pfister Fu patent opposition analysis

The comprehensive analysis of Pfister Fu opposition landscape, with a particular emphasis on intellectual property (IP) dynamics.

Stay updated with the latest patent oppositions filed by Pfister Fu

Patent NumberTitleApplicantOpposition DateOpposition Company
Treatment Of Hematologic Malignancies Associated With Circulating Tumor Cells Using Chimeric Anti-Cd20 AntibodyBIOGENJan 29, 2016NOVARTIS

Top companies who are the clients of Pfister Fu

CompanyTotal
NOVARTIS1